Onasemnogene abeparvovec may be beneficial for bulbar function in SMA type 1

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Mar 13 / Springer Healthcare

Onasemnogene abeparvovec may be beneficial for bulbar function in SMA type 1

Neuroscience Spinal Muscular Atrophy MDA-2022

Description

Katlyn McGrattan talks about a post-hoc analysis demonstrating that treatment with onasemnogene abeparvovec can achieve good bulbar function in patients with symptomatic SMA type 1.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.